![Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX]](https://cedclinic.com/wp-content/uploads/2026/06/ced-unsplash-ke6jYtwXDKA-1-150x150.jpg "Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX] 18")
#65
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
This trial provides clinicians with evidence-based dosing data for cannabidiol in neuropathic pain management, potentially offering an alternative for patients who fail or cannot tolerate conventional analgesics like gabapentin or pregabalin. Clinicians can now reference published efficacy data when counseling patients about CBD’s benefits and limitations, improving informed decision-making in their pain management strategies. The identification of effective high-dose CBD protocols enables more standardized prescribing practices rather than the current reliance on anecdotal dosing.
A randomized controlled trial published in eClinical Medicine demonstrated that high-dose cannabidiol (CBD) was superior to placebo in reducing neuropathic pain symptoms, suggesting potential therapeutic value for patients with this difficult-to-treat condition. The study findings indicate that CBD may offer an alternative or adjunctive option for neuropathic pain management, particularly for patients who have inadequate response to or intolerance of conventional analgesics. Given the prevalence of neuropathic pain in clinical practice and the limitations of existing pharmacotherapies, these results provide evidence-based support for considering CBD in appropriate patient populations. However, clinicians should note that optimal dosing regimens, long-term safety data, and comparative effectiveness relative to standard treatments still require further investigation. The practical takeaway for clinicians is that high-dose CBD now has clinical trial support for neuropathic pain, warranting consideration in discussions with eligible patients while awaiting additional evidence on dosing, duration, and long-term outcomes.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →“This randomized controlled trial adds meaningful evidence to our understanding of CBD’s role in neuropathic pain management, though we’ll want to see these findings replicated across different patient populations and dosing protocols before making it a standard recommendation in my practice.”
💊 This randomized controlled trial adds to the growing body of evidence that cannabidiol may have analgesic properties for neuropathic pain, a condition notoriously difficult to treat with conventional medications. However, clinicians should interpret these findings with appropriate caution, as neuropathic pain populations are heterogeneous, trial duration and sample sizes often remain modest, and the optimal dosing, patient selection criteria, and long-term safety profile of high-dose CBD require further clarification. The lack of FDA approval for cannabis-derived cannabinoids for pain management means prescribing remains outside standard pharmaceutical pathways in most jurisdictions, creating documentation and liability considerations for practitioners. When patients with refractory neuropathic pain inquire about CBD, a reasonable clinical approach is to acknowledge the emerging evidence while discussing the current regulatory landscape, quality and purity concerns in unregulated products, and the importance of monitoring for drug interactions and side effects if patients
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
